Evaluation of a minimally invasive glucose biosensor for continuous tissue monitoring
- 2.3k Downloads
We describe here a minimally invasive glucose biosensor based on a microneedle array electrode fabricated from an epoxy-based negative photoresist (SU8 50) and designed for continuous measurement in the dermal compartment with minimal pain. These minimally invasive, continuous monitoring sensor devices (MICoMS) were produced by casting the structures in SU8 50, crosslinking and then metallising them with platinum or silver to obtain the working and reference electrodes, respectively. The metallised microneedle array electrodes were subsequently functionalised by entrapping glucose oxidase in electropolymerised polyphenol (PP) film. Sensor performance in vitro showed that glucose concentrations down to 0.5 mM could be measured with a response times (T90) of 15 s. The effect of sterilisation by Co60 irradiation was evaluated. In preparation for further clinical studies, these sensors were tested in vivo in a healthy volunteer for a period of 3–6 h. The sensor currents were compared against point measurements obtained with a commercial capillary blood glucometer. The epoxy MICoMS devices showed currents values that could be correlated with these.
KeywordsMicroneedles Electrochemical sensor Continuous glucose monitoring (CGM)
Continuous glucose monitoring
Minimally invasive continuous monitoring sensors
Type 1 diabetes
First approved by the FDA for the management of diabetes in 1999, continuous glucose monitoring (CGM) technology has now emerged as an important diagnostic tool for detecting episodes of high blood glucose (hyperglycaemia) and low blood glucose (hypoglycaemia). The real time information on changes in glucose concentrations in terms of the direction, duration and magnitude provided by CGM devices improves glycaemic control as assessed by a reduction in the levels of glycated haemoglobin (HbA1c) . There are reports that suggest that CGM is also associated with reduction in episodes of hypoglycaemia in both children and adults with type 1 diabetes1. The advantages of regular use of CGM have been quantified; for instance, for every 1-day increase in sensor usage per week, an average HbA1c reduction of 0.15 % is observed [2, 3]. However, despite the clear benefits of continuous glucose monitoring, it has not been widely implemented in the routine management of type 1 diabetes (T1D) due to several major challenges. This is evident from T1D exchange data demonstrating that CGM technology is being used by only 6.5 % of people with type 1 diabetes in the USA (even with reimbursement), and that among those individuals who have used a CGM, two thirds subsequently stopped using it [4, 5, 6]. The major disadvantages associated with the commercially available CGM devices are their invasiveness and the associated discomfort, negatively affecting adherence and the subsequent effectiveness of CGM. Data on CGM sensor accuracy have shown clinically significant, reduced accuracy in the critical hypoglycaemic range representing another important barrier to use with a high frequency of false hypoglycaemia alarms . Finally, variable reimbursement for existing CGM systems limits access and high costs limit self-funding opportunities for people with diabetes . We have sought to address these limitations through the development of a novel electrochemical sensor based on microneedle array electrodes (MICoMS) for CGM. Earlier, we reported on the use of microneedle structures functionalised with GOx, a TTF mediator and an epoxy PU membrane for the measurement of glucose in vitro [9, 10]. However, these were unsuited for in vivo use and hence this paper describes the development of minimally invasive, continuous monitoring sensors (MICoMS) suitable for measurement in the dermal interstitial fluid.
Fabrication of microneedles for transdermal drug and vaccine delivery has been reported extensively in the literature [11, 12, 13, 14, 15, 16]. The microneedle array electrochemical sensors reported here have the potential for mass production by techniques such as injection moulding and hot embossing and thus lowering costs so they need be used for only short periods (24–48 h) before replacement. This should minimise problems associated with long-term implantation.
Materials and methods
SU-8 photoresist was obtained from Chestech Ltd, UK. Ferrocene carboxylic acid (FCA), phenol was obtained from Sigma-Aldrich, UK. Glucose oxidase (Glucose Oxidase HPS300, Activity 239 U/mg powder @25oC, source Ex Aspergillus niger) was procured from Sekisui Diagnostics (UK), Ltd. For the in vivo studies comparison, an ACCU-CHEK Aviva blood glucose system was used for intermittent capillary blood.
Fabrication of the microneedle array glucose sensor
Characterisation of microneedle devices using scanning electron microscopy (SEM)
The microneedle array electrode (MICoMS)-based continuous glucose sensor consists of a three-dimensional out-of-plane microneedle array, with 64 microneedles perpendicular to the base plate and arranged as four 4 × 4 arrays. The microneedle array electrode-based devices were characterised using a JEOL 5610 SEM. Attempts to imaging the SU8 50 microneedles in vivo using OCT were unsuccessful due to high absorbance of the material and therefore optically transparent polycarbonate structures were used instead.
Metallisation, modification of microstructure region and wire bonding to device
One of the microneedle array was masked with a tape and the remaining three coated with an adhesion layer of titanium (15 nm) followed by a platinum layer (50 nm) by conformal sputtering (DC sputter system, JLS MPS 500) in a clean room to produce three electrodes. In the next step, these three electrodes are masked and the remaining region metallised with silver (100 nm). In this work, the three platinum microneedle array electrodes are used as working electrodes and the fourth, metallised with silver, was treated with a saturated FeCl3 solution to obtain a Ag/AgCl reference electrode. The potential of the integrated reference electrode was measured against an external reference electrode and found to be higher by 30 ± 4 mV.
One millimetre holes were drilled at the periphery of the metallised part of microneedle structures, using a bench top drill. Wire bonding was done using a wrap equipment wire (RS Pro Black, Kynar Wire Wrap Equipment Wire, 0.05 mm2 CSA, 300 V 0.4 A, 50 m) run through the holes and held in place by silver conductive, adhesive paint (RS Silver Bottle Paint Conductive Adhesive) and ATACS5104 (Sigma) epoxy adhesive.
The electrode surface of the microneedle array was assessed by cyclic voltammetry (CV) using ferrocenecarboxylic acid (FCA) as a redox probe. In addition, cyclic voltammetry and chronoamperometry were performed to model the behaviour of the microneedle array electrode.
Functionalisation of the microneedle array electrode by electropolymerisation
The glucose biosensors described here were functionalised with an enzyme film using an electropolymerisation method described earlier . For the electropolymerised polyphenol, the electrode was placed in a 50 mM solution of phenol and 10 mg/mL of GOx enzyme dissolved in 100 mM PBS. The pH of the solution was buffered to pH 7.2. Each cycle comprised of holding the working electrode at 0 V for 20 s, polarising it to a potential of 0.9 V for 15 min for electropolymerisation of the film. Each cycle was repeated six times to obtain the desired film thickness and glucose oxidase loading. Following electropolymerisation, the biosensor was gently rinsed with de-ionised water and stored dry overnight at 4 °C before use.
Evaluation of GOx functionalised microneedle arrays
Dose–response curves of functionalised microneedle array electrodes
Electrochemical measurements were performed in a two-electrode configuration with CHI 1030b potentiostat (CHI Instruments) running general-purpose electrochemical software (GPES v4). To make maximum use of the platinum microneedle arrays as working electrodes, a two electrode was used. With the currents passed, there is no evidence to suggest that RE has changed its performance.
Chemical crosstalk studies
There is a possible complicating factor in any sensor array based on the detection of diffusible species. If the sensors are too close together, hydrogen peroxide generated on one electrode diffuses to another. To confirm the absence of sensor ‘chemical crosstalk’, one set of the microneedle electrodes was functionalised with glucose oxidase as described above. The other two-microneedle sets of electrodes on the same device were not functionalised.
Dose–response curves post sterilisation of functionalised microneedle array electrodes
The microneedle arrays were subjected to 25 kGy of Co60 (Synergy Health) for assay of the bio burden levels on the microneedle arrays and subsequent estimation of dose for sterilisation. These studies were done in accordance with ISO 11137-2:2012, Sterilisation of Health Care Products-Radiation-Part2: Establishing the Sterilisation dose.
In vivo studies using the microneedle array electrodes-based glucose biosensors
Sterilised microneedle array electrode-based glucose biosensors were inserted into the forearm of a healthy volunteer and their glucose concentration measured every 15 min using a finger stick glucometer. A CHI potentiostat was used to continuously bias the inserted microneedle array working electrodes at 0.7 V against the integrated counter/reference electrode with a data point being collected every 60 s. The in vivo studies were made on two separate occasions each lasting 3–6 h.
For the in vivo studies in consented healthy volunteer, approvals were obtained from the research ethics committee (REC reference: 16/LO/0007, IRAS project ID 190530).
Results and discussion
SEM characterisation of base microneedle array structures
Modelling the electrochemical behaviour of microneedle array electrodes
Most of the current decays within the first 10 s and this current, i d , was plotted against t -1/2, as shown in Fig. 4c, with the slope nFAD o C * o / (πD o )1/2. At short period of time, the Cottrell term nFAD o C * o / (πD o )1/2 dominates, and for longer period of time, it is anticipated that other factors such as convection come into play.
As seen from Fig. 4b, inset, fitted current values are higher than the experimental values at shorter time and lower at longer time. This discrepancy (approx. 3 %) is maintained throughout the later part of the 120-s measurements. At longer times, the noise is significantly lower than one would expect for a simple planar electrode. It appears that the microneedle structures may act as pillars and so stabilise the current.
Intercept and slope obtained from the Cottrell plots for microneedle array electrodes
Area of electrode (in cm2)
1.075E−05 + 0.027
2.10E−04 + 0.013
1.49E−05 + 0.034
1.85E−04 + 0.016
1.075E−05 + 0.05
2.05E−04 + 0.024
These studies provide valuable insight on the behaviour of the microneedle array electrodes in context to devices for continuous glucose sensing in the interstitial fluid. As seen from the OCT images with polycarbonate microneedles (penetration depth 800 μm), we anticipate that 80 % of the microneedle array length (from the tip) will be in contact with the ISF and the mass transport will be mainly driven by diffusion of the glucose to the sensor surface.
Evaluation of GOx functionalised microneedle array electrodes
Dose–response curves of microneedle array electrodes functionalised by phenol electropolymerisation
In total six devices were fabricated and the average K m values for all the sensor readings (n = 50) was 9.87 + 1.62 mM. Variations in K m value between the devices were seen to be larger than that between the sensors within a device. The devices showed variability in the I max between the MICoMS electrodes. The plausible reasons for this variation between the electrodes in the same device are factors such as differences in area of the MICoMS electrodes, distance of the working electrode from the reference electrode yielding variable IR drops and the total enzyme loading during electropolymerisation.
The variations in the area of the MICoMS electrodes are probably introduced during the masking step. In general, it is found that two of the electrodes give more similar current response compared to the third and this appears to correlate with the distance from the integrated reference electrode. Herein, two electrodes that agree are equidistant and the outlier slightly further away. Finally, the It curves obtained from the electro polymerisation of phenol to yield polyphenol films entrapped with GOx enzyme are different for the three MICoMS electrodes suggesting differences in enzyme loading. Normalisation of the current values with the total charge obtained from the It curves from electropolymerisation reduces the variation between the microneedle arrays.
Chemical crosstalk studies
Comparison of pre- and post sterilisation dose–response curves of functionalised microneedle array electrodes
Initial in vivo studies with the microneedle array electrodes-based glucose biosensors
Studies over short time periods (ranging from 3 to 6 h) were done using sterilised microneedle array devices. These short-term studies were undertaken for the convenience of the volunteer as it involved mobilising next to the potentiostat setup. We anticipate that these studies will provide valuable feedback on the sensor and the supporting setup that will enable development of portable bio-instrumentation around the sensor for longer time measurements.
As seen in Fig. 8a, the sensor shows an increased current value of 4500 nA in response to a glucose bolus (slice of cake in this instance) over duration of 45 min and drops back down. There is some correlation and time lag between the capillary blood and the dermal ISF (Fig. 8a, b). Whilst the dimensions are designed to obtain a minimally invasive sensor, it is evident from these in vivo studies that major operational challenge is to keep the sensors fixed in the sub-dermal space. As observed in Fig. 8b, artefacts can be seen due to movement of the arm. It is worth noting that the duration of these is much shorter than the duration of changes in glucose concentration.
There are various algorithmic approaches establishing the relationship between the measured current and glucose concentration; however, that is beyond the scope of this paper. For purposes of demonstrating the device function, we have presented unprocessed data. The sensor will be further optimised for in vivo measurements through clinical studies in healthy volunteers and subjects with T1D. For the clinical assessments, we will use the YSI measurements of venous blood, a gold standard, for the optimisation of the devices. In real life scenario, we anticipate the use of capillary blood measurements as means for calibration continuous glucose monitoring sensors.
The ability to constantly and accurately monitor blood glucose levels with a discrete device represents the top research priority for people with type 1 diabetes and specialist clinicians . One of the major barriers to achieving these priorities is sensor accuracy . Reduced sensor accuracy of existing electrochemical continuous glucose sensors is particularly evident in the hypoglycaemic range, resulting in either missed episode of hypoglycaemia or false hypoglycaemic alarms with subsequent reduced sensor reliability and patient satisfaction .
In recent years, there has been increasing interest in the use of microneedle technology for transdermal drug delivery  and for sensing of ISF analytes . By virtue of their minimally invasive nature, use of microneedle arrays is associated with no or minimal pain, no bleeding, minimal skin reaction, rapid skin recovery and a reduced infection risk. Moreover, they provide the potential to improve sensor accuracy by providing a large surface area for the electrochemical reaction providing the potential to improve the signal/noise ratio with subsequent improvement in device sensitivity and accuracy.
The use of multiple simultaneous glucose sensors improves accuracy and precision of continuous glucose monitoring . Partitioning the microneedle array into four individual 4 × 4 sub-arrays provides redundancy for technical failure of single sensors as a single malfunctioning sensor can be voted out on the basis of divergent results using conventional voting protocols.
We have demonstrated that microneedle sensors reproducibly responded to changing glucose concentrations with linear responses seen in the physiological range (0–30 mM). There was also no crosstalk between the microneedle arrays, which indicates the effectiveness of redundancy of these devices for single analyte measurement or multiplexed measurement of analytes.
Sterilisation of the microneedle devices by gamma ray irradiation did reduce the response of the device but that the devices still perform adequately, post sterilisation. The sterilised devices were stable over several days of storage at ambient conditions. The in vivo studies in human volunteer yielding measurable currents and correlation to the capillary blood measurements are important observations in preparation for clinical studies to assess safety, efficacy and correlation of the current values with that of the glucose concentration in the ISF in human subjects.
Continuous glucose monitoring technology has emerged as an important tool for management of people with diabetes. However, widespread use of this technology can only be achieved if the CGM devices become more accurate, reliable, less invasive and cost-effective.
In this paper, we describe fabrication and evaluation of a novel glucose sensor based on microneedle technology. This sensor performs electrochemically post sterilisation and can measure current in vivo when inserted in the forearm. This robust innovation has the potential to address some of the important challenges facing existing CGM devices including invasiveness, pain, accuracy and cost.
Minimally Invasive Continuous Monitoring Sensor (MICoMS)
The authors wish to acknowledge the MRC funding under the Confidence in Concept program and the NIHR funding under the Invention for Innovation scheme.
This is a summary of independent research partly funded by the National Institute for Health Research (NIHR)’s Invention for Innovation (i4i) Programme (Grant Reference Number II-LA-0313-20004). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
We would also like to thank our colleagues in the Imperial College Diabetes Technology Group, especially Professor Des Johnston, Professor Nick Oliver, Dr Pantelis Georgiou, Dr Ahmed El-Laboudi, Dr Monika Reddy and Mr. Mohamed Fayez El-Sharkawy.
The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.
Compliance with ethical standards
Imperial College-MRC, Confidence in concept program & NIHR Invention for innovation scheme
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals and informed consent
Ethics approval: In vivo studies in a healthy volunteer were carried out after approval from the research ethics committee (REC reference: 16/LO/0007, IRAS project ID 190530) and consenting.
- 24.Caffarel-Salvador E, Brady AJ, Eltayib E, Meng T, Alonso-Vicente A, Gonzalez-Vazquez P, et al. Hydrogel-forming microneedle arrays allow detection of drugs and glucose in vivo: potential for use in diagnosis and therapeutic drug monitoring. PLoS ONE. 2016;10(12), e0145644. doi: 10.1371/journal.pone.0145644.CrossRefGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.